631758

MPP PHARMA LLC — FEI 1930436

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
December 1, 2009
Fiscal Year
2010
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Kansas City, MO (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
135821 CFR 211.100(b)SOPs not followed / documented
176721 CFR 211.137(a)Expiration date lacking
181021 CFR 211.160(a)Lab controls established, including changes
189021 CFR 211.165(e)Test methods
202721 CFR 211.192Investigations of discrepancies, failures
202821 CFR 211.192Extent of discrepancy, failure investigations
360321 CFR 211.160(b)Scientifically sound laboratory controls
361621 CFR 211.165(d)Acceptance criteria for sampling & testing
440221 CFR 211.192Written record of investigation incomplete
891321 CFR 314.81(b)(2)(iv)(a)Reports re: chemical, physical, or other properties